Bifogade filer
Kurs & Likviditet
Beskrivning
Land | Danmark |
---|---|
Lista | First North Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Hørsholm, Denmark, December 9, 2021 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Pareto Securities and Analysguiden have updated their respective research reports on ExpreS2ion in December, following the publication of initial results for the phase II testing of ABNCoV2. Pareto reiterated its `buy' rating and increased its target price SEK 79 per share, based on an increased likelihood of approval.
Both research reports are available on the Analyst Reports (https://investor.expres2ionbio.com/analyst-reports/) page of ExpreS[2]ion's investor website. The next updates from Pareto Securities and Analysguiden are expected following major news.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se